Immunome, Inc. (NASDAQ:IMNM) Receives $29.00 Average PT from Brokerages

Shares of Immunome, Inc. (NASDAQ:IMNM - Get Free Report) have earned an average recommendation of "Buy" from the six brokerages that are currently covering the company, MarketBeat reports. Six research analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $29.00.

Several research analysts have recently weighed in on the company. Piper Sandler reduced their price objective on Immunome from $27.00 to $23.00 and set an "overweight" rating for the company in a research report on Tuesday, August 13th. Wedbush reaffirmed an "outperform" rating and set a $33.00 price objective on shares of Immunome in a research report on Friday, October 25th.

Immunome Stock Performance

NASDAQ:IMNM traded up $0.12 on Friday, reaching $11.59. The company's stock had a trading volume of 632,566 shares, compared to its average volume of 761,861. Immunome has a 1-year low of $6.93 and a 1-year high of $30.96. The firm has a market cap of $695.98 million, a PE ratio of -1.51 and a beta of 1.76. The business's 50-day moving average price is $13.63 and its two-hundred day moving average price is $14.02.

Immunome (NASDAQ:IMNM - Get Free Report) last posted its earnings results on Monday, August 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.11). The business had revenue of $2.36 million during the quarter, compared to analyst estimates of $2.62 million. Immunome had a negative net margin of 2,435.02% and a negative return on equity of 38.19%. As a group, sell-side analysts expect that Immunome will post -1.92 EPS for the current year.

Insider Buying and Selling

In other news, CFO Max Rosett sold 14,380 shares of the stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $16.01, for a total transaction of $230,223.80. Following the transaction, the chief financial officer now owns 47,476 shares in the company, valued at approximately $760,090.76. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Jack Higgins sold 3,524 shares of the company's stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $13.93, for a total transaction of $49,089.32. Following the completion of the sale, the insider now owns 16,000 shares of the company's stock, valued at approximately $222,880. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Max Rosett sold 14,380 shares of Immunome stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $16.01, for a total transaction of $230,223.80. Following the completion of the transaction, the chief financial officer now directly owns 47,476 shares in the company, valued at $760,090.76. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 8.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Immunome

Hedge funds and other institutional investors have recently modified their holdings of the business. Arizona State Retirement System grew its stake in shares of Immunome by 9.2% in the second quarter. Arizona State Retirement System now owns 10,862 shares of the company's stock worth $131,000 after purchasing an additional 918 shares during the last quarter. Clear Creek Financial Management LLC raised its position in Immunome by 18.2% during the 2nd quarter. Clear Creek Financial Management LLC now owns 26,188 shares of the company's stock worth $317,000 after purchasing an additional 4,035 shares during the last quarter. AQR Capital Management LLC raised its position in Immunome by 34.6% during the 2nd quarter. AQR Capital Management LLC now owns 16,064 shares of the company's stock worth $194,000 after purchasing an additional 4,129 shares during the last quarter. EntryPoint Capital LLC raised its position in Immunome by 21,864.0% during the 1st quarter. EntryPoint Capital LLC now owns 5,491 shares of the company's stock worth $136,000 after purchasing an additional 5,466 shares during the last quarter. Finally, Quest Partners LLC bought a new position in Immunome during the 2nd quarter worth $81,000. Institutional investors own 44.58% of the company's stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.